DV Biomed Co., Ltd. (TPEX:6539)
Taiwan
· Delayed Price · Currency is TWD 54.20
+0.70 (1.31%)
Mar 10, 2026, 9:17 AM CST
DV Biomed Revenue
DV Biomed had revenue of 387.75M TWD in the half year ending June 30, 2025, with 19.17% growth. This brings the company's revenue in the last twelve months to 712.61M, up 22.75% year-over-year. In the year 2024, DV Biomed had annual revenue of 573.57M, down -7.32%.
Revenue (ttm)
712.61M
Revenue Growth
+22.75%
P/S Ratio
1.83
Revenue / Employee
2.19M
Employees
326
Market Cap
1.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 573.57M | -45.28M | -7.32% |
| Dec 31, 2023 | 618.85M | -1.25B | -66.84% |
| Dec 31, 2022 | 1.87B | 38.99M | 2.13% |
| Dec 31, 2021 | 1.83B | 15.42M | 0.85% |
| Dec 31, 2020 | 1.81B | -118.69M | -6.15% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Excelsior Biopharma | 898.26M |
| Winston Medical Supply | 724.35M |
| Anxo Pharmaceutical | 883.22M |
| Original BioMedicals | 381.00K |
| InnoPharmax | 55.77M |
| Tien Liang BioTech | 467.02M |
| Mediera | 229.85M |
| Prince Pharmaceutical | 798.27M |